Tumor‐induced variations of ANGPTL3 [56] and uptake of HDL‐cholesterol by cancer cells [57] have been reported, perhaps explaining the disruption between ANGPTL3 levels and HDL in ovarian and prostate cancers. This evidence concerns the gene ANGPTL3 and prostate carcinoma.